Ken Fisher's BMY Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 216,142 shares of Bristol-Myers Squibb Company (BMY) worth $9.75 M, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in BMY, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2016, adding 501,260 shares. Largest reduction occurred in Q1 2020, reducing 309,852 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Bristol-Myers Squibb Company (BMY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bristol-Myers Squibb Company (BMY) Trades by Ken Fisher
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +14,504 | Add 0.00% | 14,503 | $44.68 |
| Q3 2013 | +1,434 | Add 9.89% | 15,937 | $46.31 |
| Q4 2013 | +2,201 | Add 13.81% | 18,138 | $53.15 |
| Q1 2014 | -2,405 | Reduce 13.26% | 15,733 | $51.93 |
| Q2 2014 | +33,999 | Add 216.10% | 49,732 | $48.52 |
| Q3 2014 | +1,469 | Add 2.95% | 51,201 | $51.17 |
| Q4 2014 | -20,462 | Reduce 39.96% | 30,739 | $59.05 |
| Q1 2015 | +1,702 | Add 5.54% | 32,441 | $64.49 |
| Q2 2015 | +2,195 | Add 6.77% | 34,636 | $66.55 |
| Q3 2015 | +26,544 | Add 76.64% | 61,180 | $59.20 |
| Q4 2015 | +73,620 | Add 120.33% | 134,800 | $68.79 |
| Q1 2016 | +501,260 | Add 371.85% | 636,060 | $68.05 |
| Q2 2016 | +12,047 | Add 1.89% | 648,107 | $75.39 |
| Q3 2016 | +2,225 | Add 0.34% | 650,332 | $53.92 |
| Q4 2016 | +3,398 | Add 0.52% | 653,730 | $58.44 |
| Q1 2017 | +12,534 | Add 1.92% | 666,264 | $54.38 |
| Q2 2017 | -159,237 | Reduce 23.90% | 507,027 | $55.72 |
| Q3 2017 | -2,534 | Reduce 0.50% | 504,493 | $63.74 |
| Q4 2017 | +77,720 | Add 15.41% | 582,213 | $61.28 |
| Q1 2018 | -5,132 | Reduce 0.88% | 577,081 | $63.25 |
| Q2 2018 | +4,229 | Add 0.73% | 581,310 | $55.34 |
| Q3 2018 | -72,067 | Reduce 12.40% | 509,243 | $62.08 |
| Q4 2018 | -15,165 | Reduce 2.98% | 494,078 | $51.98 |
| Q1 2019 | +82,239 | Add 16.64% | 576,317 | $47.71 |
| Q2 2019 | -57,882 | Reduce 10.04% | 518,435 | $45.35 |
| Q3 2019 | -1,734 | Reduce 0.33% | 516,701 | $50.71 |
| Q4 2019 | -7,375 | Reduce 1.43% | 509,326 | $64.19 |
| Q1 2020 | -309,852 | Reduce 60.84% | 199,474 | $55.74 |
| Q2 2020 | -27,191 | Reduce 13.63% | 172,283 | $58.80 |
| Q3 2020 | +3,059 | Add 1.78% | 175,342 | $60.29 |
| Q4 2020 | +3,799 | Add 2.17% | 179,141 | $62.03 |
| Q1 2021 | -3,783 | Reduce 2.11% | 175,358 | $63.13 |
| Q2 2021 | -1,665 | Reduce 0.95% | 173,693 | $66.82 |
| Q3 2021 | +18,040 | Add 10.39% | 191,733 | $59.17 |
| Q4 2021 | +251,210 | Add 131.02% | 442,943 | $62.35 |
| Q1 2022 | -13,132 | Reduce 2.96% | 429,811 | $73.03 |
| Q2 2022 | -4,011 | Reduce 0.93% | 425,800 | $77.00 |
| Q3 2022 | -38,024 | Reduce 8.93% | 387,776 | $71.09 |
| Q4 2022 | -189,036 | Reduce 48.75% | 198,740 | $71.95 |
| Q1 2023 | +5,512 | Add 2.77% | 204,252 | $69.31 |
| Q2 2023 | +40,941 | Add 20.04% | 245,193 | $63.95 |
| Q3 2023 | -147,884 | Reduce 60.31% | 97,309 | $58.04 |
| Q4 2023 | +126,122 | Add 129.61% | 223,431 | $51.31 |
| Q1 2024 | +2,322 | Add 1.04% | 225,753 | $54.23 |
| Q2 2024 | +2,245 | Add 0.99% | 227,998 | $41.53 |
| Q3 2024 | -1,518 | Reduce 0.67% | 226,480 | $51.74 |
| Q4 2024 | -2,603 | Reduce 1.15% | 223,877 | $56.56 |
| Q1 2025 | -3,138 | Reduce 1.40% | 220,739 | $60.99 |
| Q2 2025 | +6,237 | Add 2.83% | 226,976 | $46.29 |
| Q3 2025 | -10,834 | Reduce 4.77% | 216,142 | $45.10 |
Ken Fisher's Bristol-Myers Squibb Company Investment FAQs
Ken Fisher first purchased Bristol-Myers Squibb Company (BMY) in Q2 2013, acquiring 14,503 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Bristol-Myers Squibb Company (BMY) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher's largest addition to Bristol-Myers Squibb Company (BMY) was in Q1 2016, adding 636,060 shares worth $43.28 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 216,142 shares of Bristol-Myers Squibb Company (BMY), valued at approximately $9.75 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bristol-Myers Squibb Company (BMY) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher's peak holding in Bristol-Myers Squibb Company (BMY) was 666,264 shares, as reported at the end of Q1 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.